SC
LRMR icon

Stempoint Capital’s Larimar Therapeutics LRMR Stock Holding History

Stempoint Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-704,349
Closed -$5.11M – 64
2024
Q2 		$5.11M Sell
704,349
-36,528
-5% -$280K 1.5% 22
2024
Q1 		$5.62M Sell
740,877
-42,295
-5% -$330K 1.49% 20
2023
Q4 		$3.56M Buy
+783,172
New +$2.64M 0.95% 37

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Stempoint Capital's LRMR Position: Q3 2024 in Review

Stempoint Capital sold out of Larimar Therapeutics (LRMR) in Q3 2024, closing a stake of 704,349 shares — an estimated $5.11M sold.

Stempoint Capital first reported a position in LRMR in Q4 2023 and held it in 3 quarters. The position peaked at $5.62M in Q1 2024. 123 funds tracked by Wall St. Rank hold LRMR as of Q3 2024.

  • Stempoint Capital reported no remaining Larimar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Stempoint Capital sold 704,349 Larimar Therapeutics shares in Q3 2024, an estimated $5.11M.
  • Stempoint Capital first reported a position in Larimar Therapeutics in Q4 2023 and held it in 3 quarters.
  • Stempoint Capital's Larimar Therapeutics position peaked at $5.62M in Q1 2024.
  • 123 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2024.

Based on Stempoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.